Pharma/fine chemicals roundup—17 December 2013
4:46 AM MST | December 17, 2013 | By DEEPTI RAMESH
ScinoPharm opens API plant in Changshu; plans to expand site
ScinoPharm (Tainan, Taiwan) says that it has completed the construction of a new facility at Changshu, China, and the new site includes a multipurpose active pharmaceutical ingredient (API) manufacturing plant, and an R&D process development center. A total of $113 million was invested in the new facility. ScinoPharm says it has also signed an agreement with the economical development zone to purchase an additional 108 acres adjacent to the new facility, in order to expand API production in the future and for the construction of formulation production plants.
Ampac Fine Chemicals reports fall in profits and sales
Ampac Fine Chemicals (AFC; Rancho Cordova, CA), a subsidiary of American Pacific (Las Vegas), reports an 88.2% fall in operating profits for its fiscal fourth quarter ended 30 September 2013, compared with the year-ago period, to $463,000. Fourth-quarter sales decreased 33.3%, to $22.06 million.
For the full fiscal year ended 30 September, AFC recorded a 61.4% increase in operating profits compared with the previous fiscal year, to $11.3 million. Full-year sales increased 12%, to $124.9 million. The rise in full-year sales was led by increases in development product revenues, AFC says.
Shasun to sell API plant at Vishakhapatnam
Shasun Pharmaceuticals (Chennai, India), a manufacturer of active pharmaceutical ingredients (APIs) and formulations, says that its board of directors has approved plans to divest its API manufacturing facility at Vishakhapatnam, India, subject to approval from shareholders. The company announced in 2009 that it plans to build the facility with an initial production capacity of 1,200 m.t./year of bulk drugs, including generic APIs, particularly for the Japanese market. Completion of the facility was delayed several times due to several reasons, including Shasun’s consolidation of operations at its Puducherry and Cuddalore facilities and disruption of operations at these units.
Global excipients market to reach $7.58 billion in 2018
The global excipients demand was worth $5.26 billion in 2011 and is expected to reach $7.58 billion in 2018, growing at a CAGR of 5.4% from 2013 to 2018 says a new report by Transparency Market Research. Europe currently dominates the global market in terms of demand; however Asia/Pacific is expected to be the most promising market in the near future mainly due to the availability of low-cost products and cheap labor, the report says. The North America market for excipients in terms of revenue is growing at a CAGR of 5.3% from 2013 to 2018 as the United States has the biggest pharmaceutical market globally, the report says.
FDA completes inspection of Cambrex API facility at Charles City
Cambrex (East Rutherford, NJ) says that the US Food and Drug Administration (FDA) completed an inspection of Cambrex's active pharmaceutical ingredient (API) manufacturing facility at Charles City, IA. The US FDA authorities inspected the facility from 31 July to 1 August, 2013. The inspection found the site to be compliant with good manufacturing practice (GMP), Cambrex says. In May 2013, the company completed an expansion of its Charles City facility. The expanded facility is a large-scale, multipurpose API facility that is capable of handling potent products.
Lonza and BioWa sign licensing agreement with AstraZeneca
Lonza and BioWa (La Jolla, CA), a wholly owned subsidiary of biopharmaceutical company Kyowa Hakko Kirin (Tokyo), have entered into a licensing agreement with MedImmune (Gaithersburg, MD), the global biologics R&D arm of AstraZeneca (London). MedImmune has licensed the companies’ Potelligent CHOK1SV cell line technology for use in multiple proprietary antibodies in its pipeline. MedImmune entered into a previous licensing agreement with BioWa in 2007 for Potelligent technology. The latest agreement incorporates Lonza’s technology to the existing Potelligent technology. Potelligent CHOK1SV is a host cell line for manufacturing recombinant antibodies.
Merck KGaA to invest $55 million to build pharma facility
Merck KGaA says that it has begun construction on a new pharmaceutical production facility at Reinbek near Hamburg, Germany, for its Allergopharma unit. The new facility will involve an investment of about €40 million ($55 million) and will be used to expand production to serve new markets such as China, the company says. Construction is expected to be completed in 2016, and the facility will produce products for the diagnosis and treatment of type 1 allergies such as hay fever or allergic asthma.
Connect with IHS Chemical Week
Our related sites